NCT05779241: Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
- State
- Completed
- Phase
- Phase 3
- People
- 83 taking part
- Started
- 13 Apr 2023
- Primary completion
- 3 Nov 2023
- Arms
- LYN-005 Containing 15-mg Risperidone, LYN-005 Containing 45-mg Risperidone
- Results
- None posted
- 22 Mar 2023: Trial registered
- 13 Apr 2023: Trial started
- 1 Dec 2023: Trial completed